Brief: Matinas Biopharma Resumes Enrollment In The Enhance-It And Enact Clinical Trials
30/06/2020 22:15
June 30 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA RESUMES ENROLLMENT IN THE ENHANCE-IT AND
ENACT
CLINICAL TRIALS
* MATINAS BIOPHARMA - TOPLINE DATA FROM ENHANCE-IT STUDY OF
MAT9001 VERSUS. VASCEPA EXPECTED IN Q1 2021
* MATINAS BIOPHARMA - ENACT REMAINS ON TRACK FOR COHORT
PROGRESSION IN Q4 2020
* MATINAS BIOPHARMA - EXPECTS TO COMPLETE ENROLLMENT IN
ENHANCE-IT
STUDY IN AUGUST OF 2020
Source text for Eikon: ID:nGNX1nLnWP
Further company coverage: MTNB.A
(Reuters.Briefs@thomsonreuters.com)
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing